R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Dr Cedrik Britten, chief medical officer at Immatics, discusses novel PRAME-directed T-cell immunotherapies.

R&D

As increasing global competition from incentives is felt globally, Ireland needs to become even more agile.

R&D

LUCENT Biopharma's Medical Director Matthew Goodman, a doctor by training, specialises in late-phase Clinical Development and Medical Affairs.

R&D

Dr Shai Melcer, head of bio-convergence at the Israel Innovation Authority, discusses biology as a language ahead of Biomed Israel 2026.

R&D

A review of the scope, key principles, methodological expectations, and regulatory implications of ICH E20.